NL-OMON46879已完成4 期
Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV) - Maximal Medical Therapy Achieved with SIMBRINZA and DUOTRAV
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- ovartis
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Subjects 18 years of age or older, of any race, diagnosed with either open-angle glaucoma (including pseudo exfoliation or pigment dispersion glaucoma) or ocular hypertension
- •2. Subjects currently on treatment with Travoprost 0.004% / Timolol 0.5% prescribed as approved in the country, on morning or evening dosing for at least 28 days prior to screening and that in the opinion of the Investigator may benefit from further IOP lowering
- •3. Qualifying mean IOP measurements at both the Eligibility 1 and Eligibility 2 visits, in at least 1 eye (the same eye(s) * 19 and * 28 mmHg at 9:00 while on a Travoprost 0.004% / Timolol 0.5% solution)
- •4. Must be able to understand and sign an informed consent form that has been approved by an Institutional Review Board/Ethics Committee
- •5. Willing and able to attend all study visits
排除标准
- •1. Women of childbearing potential (WOCBP), defined as all women who are not postmenopausal for at least 1 year or less than 6 weeks since sterilization, are excluded from participation if: a. they are currently pregnant, or // b. have a positive result on the urine pregnancy test at Screening, or // c. intend to become pregnant during the study period, or // d. are breast-feeding, or // e. are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
- •All women of childbearing potential are required to use adequate birth control methods which are summarized as follows: a. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception. // b. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before Baseline. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. // c. Male sterilization (at least 6 months prior to Baseline). For female subjects in the study, the vasectomized male partner should be the sole partner for that subject. // d. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. // e. Placement of an intrauterine device (IUD) or intrauterine system (IUS).;2. Subjects with any form of glaucoma other than open-angle glaucoma or ocular hypertension.
- •3. Subjects with central cornea thickness (CCT) greater than 620 *m as measured by pachymetry in either eye.
- •4. Subjects with Schaffer angle Grade < 2 in either eye, as measured by gonioscopy (extreme narrow angle with complete or partial closure).
- •5. Subjects with cup/disc ratio greater than 0.80 (horizontal or vertical measurement) in either eye.
- •6. Subjects with severe central visual field loss in either eye or field loss threatening fixation in either eye.
- •7. Subjects with chronic, recurrent or severe inflammatory eye disease (eg, scleritis, uveitis, herpes keratitis) in either eye.
- •8. Subjects with ocular trauma in either eye within the past 6 months prior to the Screening visit.
- •9. Subjects with ocular infection or ocular inflammation in either eye within the past 3 months prior to the Screening visit.
- •10. Subjects with clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment in either eye.
- •11. Subjects with best-corrected visual acuity score worse than 55 ETDRS letters (equivalent to approximately 20/80 Snellen, 0.60 logMAR or 0.25 decimal) in either eye.
- •12. Subjects with other ocular pathology (including severe dry eye) in either eye that may, in the opinion of the Investigator, preclude the safe administration of any study medication.
- •13. Subjects with intraocular surgery in either eye within the past 6 months prior to the Screening visit.
- •14. Subjects with ocular laser surgery in either eye within the past 3 months prior to the Screening visit.
- •15. Subjects with any abnormality preventing reliable applanation tonometry in either eye.
- •16. Any other conditions including severe illness which would make t
研究者
相似试验
已完成
3 期
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)ALSAmyotrophic Lateral Sclerosis10011305NL-OMON44970AB Science10
已完成
2 期
A multicenter, phase II study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo amyloid light chain (AL) amyloidosisAL amyloidosis10035227NL-OMON39975HOVO40
已完成
3 期
A European Multicentre Double-Blind Placebo Controlled trial of Nilvadipine in Mild to Moderate Alzheimer*s diseaseAlzheimer disease10029305dementiaNL-OMON37208niversitair Medisch Centrum Sint Radboud77
已完成
2 期
A multicentre randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety, tolerability, efficacy, dose-response, pharmacokinetics and pharmacodynamics of repeat dosing of an anti-LAG3 cell depleting monoclonal antibody (GSK2831781) in patients with active ulcerative colitisUlcerative colitisinflamatory bowel disease10017969NL-OMON49796GlaxoSmithKline3
已完成
2 期
A randomised, controlled, double-blind trial to investigate the effects of a new infant formula on growth, tolerance and safety in healthy term infants.effect op de groei van zuigelingeneffects on growthNL-OMON39783utricia Research - Centre for Specialised Nutrition121